カテゴリー： QYResearch, 世界

巣状分節性糸球体硬化症（FSGS）治療の世界市場規模・現状・予測2021年-2027年

QYResearchが発行した調査報告書（QY21APR2418）
◆英語タイトル：Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size, Status and Forecast 2021-2027
◆商品コード：QY21APR2418
◆発行会社（リサーチ会社）：QYResearch
◆発行日：2021年4月
◆ページ数：95
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後3営業日）
◆調査対象地域：グローバル
◆産業分野：医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,900 ⇒換算￥499,200見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD5,850 ⇒換算￥748,800見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。
本調査資料では、巣状分節性糸球体硬化症（FSGS）治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（薬物療法、透析、腎臓移植）、用途別市場規模（一次FSGS、二次FSGS）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。
・市場概要
・巣状分節性糸球体硬化症（FSGS）治療の市場動向
・企業の競争状況、市場シェア
・巣状分節性糸球体硬化症（FSGS）治療の種類別市場規模（薬物療法、透析、腎臓移植）
・巣状分節性糸球体硬化症（FSGS）治療の用途別市場規模（一次FSGS、二次FSGS）
・巣状分節性糸球体硬化症（FSGS）治療の北米市場規模2016-2027（アメリカ、カナダ）
・巣状分節性糸球体硬化症（FSGS）治療の欧州市場規模2016-2027（ドイツ、フランス、イギリス等）
・巣状分節性糸球体硬化症（FSGS）治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・巣状分節性糸球体硬化症（FSGS）治療の中南米市場規模2016-2027（メキシコ、ブラジル）
・巣状分節性糸球体硬化症（FSGS）治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（B. Braun Melsungen、Medtronic、Pfizer、Complexa、Dimerix、Retrophin、Beckman Coulter Inc. (Danaher)、Boston Scientific Corporation、ChemoCentryx、Variant Pharmaceuticals）
・結論
【レポートの概要】

Focal segmental glomerulosclerosis (FSGS) is a type of rare kidney disease that affects the kidney’s filtering system (glomeruli) resulting in proteinuria and serious scarring. Focal segmental glomerulosclerosis (FSGS) is usually fatal since it causes kidney failure within four to nine years followed by dialysis and then death. FSGS advances much more swiftly than diabetic nephropathy. Massive proteinuria, nephrotic syndrome, edema, hyperlipidemia, and hypoalbuminemia are some of the common symptoms of the disease. Risk factors include obesity, infection, sickle cell disease and reflux nephropathy.
The market for FSGS treatment is primarily driven by the increasing disease burden, rising focus towards rare diseases, and increased R&D activity. Geographical analysis shows that North America is expected to maintain its dominance in this market, particularly due to well-structured healthcare facilities, early adoption of therapies and diagnosis options, and better reimbursement policies, as compared to other regions.

Market Analysis and Insights: Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market
The global Focal Segmental Glomerulosclerosis (FSGS) Treatment market size is projected to reach US$ 414.3 million by 2026, from US$ 308.5 million in 2019, at a CAGR of 4.3% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Focal Segmental Glomerulosclerosis (FSGS) Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Focal Segmental Glomerulosclerosis (FSGS) Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Focal Segmental Glomerulosclerosis (FSGS) Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Focal Segmental Glomerulosclerosis (FSGS) Treatment market.

Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Scope and Market Size
Focal Segmental Glomerulosclerosis (FSGS) Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Focal Segmental Glomerulosclerosis (FSGS) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Drug Therapy
Dialysis
Kidney Transplant

Segment by Application
Primary FSGS
Secondary FSGS

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
B. Braun Melsungen
Medtronic
Pfizer
Complexa
Dimerix
Retrophin
Beckman Coulter Inc. (Danaher)
Boston Scientific Corporation
ChemoCentryx

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Drug Therapy
1.2.3 Dialysis
1.2.4 Kidney Transplant
1.3 Market by Application
1.3.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Primary FSGS
1.3.3 Secondary FSGS
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Perspective (2016-2027)
2.2 Focal Segmental Glomerulosclerosis (FSGS) Treatment Growth Trends by Regions
2.2.1 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Focal Segmental Glomerulosclerosis (FSGS) Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Focal Segmental Glomerulosclerosis (FSGS) Treatment Industry Dynamic
2.3.1 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Trends
2.3.2 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Drivers
2.3.3 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Challenges
2.3.4 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Focal Segmental Glomerulosclerosis (FSGS) Treatment Players by Revenue
3.1.1 Global Top Focal Segmental Glomerulosclerosis (FSGS) Treatment Players by Revenue (2016-2021)
3.1.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue
3.4 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Concentration Ratio
3.4.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue in 2020
3.5 Focal Segmental Glomerulosclerosis (FSGS) Treatment Key Players Head office and Area Served
3.6 Key Players Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Solution and Service
3.7 Date of Enter into Focal Segmental Glomerulosclerosis (FSGS) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Focal Segmental Glomerulosclerosis (FSGS) Treatment Breakdown Data by Type
4.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Historic Market Size by Type (2016-2021)
4.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecasted Market Size by Type (2022-2027)

5 Focal Segmental Glomerulosclerosis (FSGS) Treatment Breakdown Data by Application
5.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Historic Market Size by Application (2016-2021)
5.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size (2016-2027)
6.2 North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type
6.2.1 North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2016-2021)
6.2.2 North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2022-2027)
6.2.3 North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2016-2027)
6.3 North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application
6.3.1 North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2016-2021)
6.3.2 North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2022-2027)
6.3.3 North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2016-2027)
6.4 North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country
6.4.1 North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country (2016-2021)
6.4.2 North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size (2016-2027)
7.2 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type
7.2.1 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2016-2021)
7.2.2 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2022-2027)
7.2.3 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2016-2027)
7.3 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application
7.3.1 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2016-2021)
7.3.2 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2022-2027)
7.3.3 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2016-2027)
7.4 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country
7.4.1 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country (2016-2021)
7.4.2 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size (2016-2027)
8.2 Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type
8.2.1 Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application
8.3.1 Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Region
8.4.1 Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size (2016-2027)
9.2 Latin America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type
9.2.1 Latin America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2016-2027)
9.3 Latin America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application
9.3.1 Latin America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2016-2027)
9.4 Latin America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country
9.4.1 Latin America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size (2016-2027)
10.2 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type
10.2.1 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application
10.3.1 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country
10.4.1 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 B. Braun Melsungen
11.1.1 B. Braun Melsungen Company Details
11.1.2 B. Braun Melsungen Business Overview
11.1.3 B. Braun Melsungen Focal Segmental Glomerulosclerosis (FSGS) Treatment Introduction
11.1.4 B. Braun Melsungen Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021)
11.1.5 B. Braun Melsungen Recent Development
11.2 Medtronic
11.2.1 Medtronic Company Details
11.2.2 Medtronic Business Overview
11.2.3 Medtronic Focal Segmental Glomerulosclerosis (FSGS) Treatment Introduction
11.2.4 Medtronic Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021)
11.2.5 Medtronic Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Focal Segmental Glomerulosclerosis (FSGS) Treatment Introduction
11.3.4 Pfizer Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021)
11.3.5 Pfizer Recent Development
11.4 Complexa
11.4.1 Complexa Company Details
11.4.2 Complexa Business Overview
11.4.3 Complexa Focal Segmental Glomerulosclerosis (FSGS) Treatment Introduction
11.4.4 Complexa Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021)
11.4.5 Complexa Recent Development
11.5 Dimerix
11.5.1 Dimerix Company Details
11.5.2 Dimerix Business Overview
11.5.3 Dimerix Focal Segmental Glomerulosclerosis (FSGS) Treatment Introduction
11.5.4 Dimerix Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021)
11.5.5 Dimerix Recent Development
11.6 Retrophin
11.6.1 Retrophin Company Details
11.6.2 Retrophin Business Overview
11.6.3 Retrophin Focal Segmental Glomerulosclerosis (FSGS) Treatment Introduction
11.6.4 Retrophin Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021)
11.6.5 Retrophin Recent Development
11.7 Beckman Coulter Inc. (Danaher)
11.7.1 Beckman Coulter Inc. (Danaher) Company Details
11.7.2 Beckman Coulter Inc. (Danaher) Business Overview
11.7.3 Beckman Coulter Inc. (Danaher) Focal Segmental Glomerulosclerosis (FSGS) Treatment Introduction
11.7.4 Beckman Coulter Inc. (Danaher) Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021)
11.7.5 Beckman Coulter Inc. (Danaher) Recent Development
11.8 Boston Scientific Corporation
11.8.1 Boston Scientific Corporation Company Details
11.8.2 Boston Scientific Corporation Business Overview
11.8.3 Boston Scientific Corporation Focal Segmental Glomerulosclerosis (FSGS) Treatment Introduction
11.8.4 Boston Scientific Corporation Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021)
11.8.5 Boston Scientific Corporation Recent Development
11.9 ChemoCentryx
11.9.1 ChemoCentryx Company Details
11.9.2 ChemoCentryx Business Overview
11.9.3 ChemoCentryx Focal Segmental Glomerulosclerosis (FSGS) Treatment Introduction
11.9.4 ChemoCentryx Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021)
11.9.5 ChemoCentryx Recent Development
11.10 Variant Pharmaceuticals
11.10.1 Variant Pharmaceuticals Company Details
11.10.2 Variant Pharmaceuticals Business Overview
11.10.3 Variant Pharmaceuticals Focal Segmental Glomerulosclerosis (FSGS) Treatment Introduction
11.10.4 Variant Pharmaceuticals Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021)
11.10.5 Variant Pharmaceuticals Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details



【免責事項】
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 巣状分節性糸球体硬化症（FSGS）治療の世界市場規模・現状・予測2021年-2027年(Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size, Status and Forecast 2021-2027)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 遅発性ジスキネジア（TD）治療の世界市場規模・現状・予測2021年-2027年 Tardive dyskinesia (TD) is a neurological disorder that has the involvement of the involuntary movements. The terms can be described as tardive which means delayed and dyskinesia which means abnormal movement. The symptoms of tardive dyskinesia include finger movement, facial grimacing, jaw swinging, repetitive chewing, continuous blinking of the eyes, tongue thrusting, and others.  Market Analysis and Insights: Global Tardive Dyskinesia (TD) Treatment Market The global Tardive Dyskinesia (TD) Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and...
  • 遅発性ジスキネジア（TD）治療の世界市場規模・現状・予測2021年-2027年 Tardive dyskinesia (TD) is a neurological disorder that has the involvement of the involuntary movements. The terms can be described as tardive which means delayed and dyskinesia which means abnormal movement. The symptoms of tardive dyskinesia include finger movement, facial grimacing, jaw swinging, repetitive chewing, continuous blinking of the eyes, tongue thrusting, and others.  Market Analysis and Insights: Global Tardive Dyskinesia (TD) Treatment Market The global Tardive Dyskinesia (TD) Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and...
  • 髄膜炎診断・治療の世界市場規模・現状・予測2021年-2027年 Meningitis is an acute inflammation of the protective membranes covering the brain and spinal cord, known collectively as the meninges. The most common symptoms are fever, headache, and neck stiffness. Other symptoms include confusion or altered consciousness, vomiting, and an inability to tolerate light or loud noises. Young children often exhibit only nonspecific symptoms, such as irritability, drowsiness, or poor feeding. If a rash is present, it may indicate a particular cause of meningitis; for instance, meningitis caused by meningococcal bacteria may be accompanied by a characteristic rash. In 2015 meningitis occurred in about 8.7 million people worldwide. This resulted...
  • 脊髄性筋萎縮症（SMA）治療の世界市場規模・現状・予測2021年-2027年 Spinal muscular atrophy (SMA) refers to a group of inherited diseases that affects the functioning of muscles because of deterioration. North America dominates the global market for SMA treatment due to the high prevalence of SMA and increased adoption of SMA treatment options in the region. Market Analysis and Insights: Global Spinal Muscular Atrophy (SMA) Treatment Market The global Spinal Muscular Atrophy (SMA) Treatment market size is projected to reach US$ 1441.4 million by 2026, from US$ 874.6 million in 2019, at a CAGR of 7.3% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the report makes...
  • 急性間欠性ポルフィリン症（AIP）治療の世界市場規模・現状・予測2021年-2027年 Acute intermittent porphyria (AIP), also called Swedish porphyria, pyrroloporphyria, intermittent acute porphyria) is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deaminase. It is the most common of the acute porphyrias. Market Analysis and Insights: Global Acute Intermittent Porphyria Treatment Market The global Acute Intermittent Porphyria Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Acute Intermittent Porphyria Treatment market to help...
  • 顕微鏡的多発血管炎（MPA）治療の世界市場規模・現状・予測2021年-2027年 Market Analysis and Insights: Global Microscopic Polyangiitis (MPA) Treatment Market The global Microscopic Polyangiitis (MPA) Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Microscopic Polyangiitis (MPA) Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Microscopic Polyangiitis (MPA)...
  • 神経精神障害＆治療の世界市場規模・現状・予測2021年-2027年 Neuropsychiatric disorder is a blanket medical term that encompasses a broad range of medical conditions that involve both neurology and psychiatry. Common neuropsychiatric disorders include seizures, attention deficits, cognitive deficits, palsies, uncontrolled anger, migraine headaches, addictions, eating disorders, depression, and anxiety and others. They can range widely in cause, course, and severity. The key component of neuropsychiatric disorders is that the symptoms tend to impact brain function, emotion and mood. These can range from problems with focus and learning in the case of ADHD to sadness, irritability, memory problems, mood problems, depression to a variety of other psychiatric and/or neurological...
  • HIV診断＆治療の世界市場規模・現状・予測2021年-2027年 HIV prevalence in Africa, specifically in Southern region is very high as compared to North African region. Approximately 1 out of 4 is suffering from HIV. Southern and Eastern region of Africa has one of the highest prevalence rate of HIV, about 19 million people have HIV. While HIV prevalence is low in North Africa but the number of cases of HIV are increasing rapidly. There is no cure for HIV but drugs manufacturing companies are investing huge money in R&D to develop drugs for HIV. Over 3000 patients were died in sub Saharan Africa due to HIV in 2015....
  • てんかん診断・治療の世界市場規模・現状・予測2021年-2027年 Epilepsy is a neurological disorder affecting the central nervous system. In this medical condition, the brain exhibits abnormal activity, which results in periods of unusual behavior or seizures and sometimes, loss of awareness. Temporary confusion, anxiety, uncontrollable jerking movements of the arms and legs, and others are some of the common symptoms of the disease. Increasing prevalence of epilepsy is a major driver for the market. According to a report by the World Health Organization (2018), about 50 million people across the world are estimated to suffer from epilepsy, making it one of the most common neurological diseases. In addition,...
  • アデノシンデアミナーゼ欠損症（ADA）治療の世界市場規模・現状・予測2021年-2027年 Adenosine deaminase deficiency is an autosomal recessive metabolic disorder that causes immunodeficiency. It occurs in fewer than one in 100,000 live births worldwide. Market Analysis and Insights: Global Adenosine Deaminase Deficiency Treatment Market The global Adenosine Deaminase Deficiency Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Adenosine Deaminase Deficiency Treatment market to help players in achieving a strong market position. Buyers of the report can...
  • HIV診断・治療の世界市場規模・現状・予測2021年-2027年 Market Analysis and Insights: Global HIV Diagnosis and Treatment Market The global HIV Diagnosis and Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global HIV Diagnosis and Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global HIV Diagnosis and...
  • 再発性多形性膠芽腫（GBM）治療の世界市場規模・現状・予測2021年-2027年 Recurrent glioblastoma multiforme is the most aggressive cancer that begins within the brain. The increasing incidence of seizure is expected to drive the recurrent glioblastoma multiforme treatment market. Market Analysis and Insights: Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market The global Recurrent Glioblastoma Multiforme (GBM) Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Recurrent Glioblastoma Multiforme (GBM) Treatment market to...
  • 神経性食欲不振症（AN）治療の世界市場規模・現状・予測2021年-2027年 Anorexia nervosa is a dietary disorder or eating disorder portrayed by an irregular low body weight, risky fear of putting on weight and a misshaped view of body weight. Individuals with anorexia put a high incentive on controlling their weight and shape, utilizing outrageous endeavors that have a tendency to fundamentally meddle with exercises in daily their lives. Individuals with anorexia ordinarily extremely limit the amount of nourishment they eat. Individuals may control calories by vomiting after eating or by abusing intestinal medicines etc. They may likewise endeavor to get more fit by practicing too much. Symptoms may include weight...
  • 水痘帯状疱疹ウイルス（VZV）治療の世界市場規模・現状・予測2021年-2027年 Market Analysis and Insights: Global Varicella-Zoster Virus (VZV) Treatment Market The global Varicella-Zoster Virus (VZV) Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Varicella-Zoster Virus (VZV) Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Varicella-Zoster Virus (VZV)...
  • 経口血糖降下薬（OAD）治療の世界市場規模・現状・予測2021年-2027年 Diabetic is the condition where the sugar (glucose) level is high in the blood or the production of the insulin is inadequate. Diabetes main type the very first one is Type 1 and the second is Type 2, both the diabetic are most commonly find in the current scenario, apart from this many other diabetics case are also been listed as gestational diabetes and others. Various treatment method are present in the market injection, oral and others. The mostly used method of treatment or managing the diabetes is the oral. North America has the 44.3 million population with diabetes in...